Michelle Chen, Ph.D. is a biotech executive and industry leader with extensive experience in strategy, business and corporate development, M&A, investor relations, ventures, fundraising, and R&D. She currently serves as President, CEO and Board Member of Form Bio, the first spin-off from Colossal Biosciences, where she leads company’s efforts to harness AI for genetic medicine design and genome engineering applications.Prior to Form Bio, Michelle served as Chief Business Officer at Insilico Medicine, where she drove the company’s growth by translating cutting-edge AI technologies into high-value drug discovery and platform partnerships—unlocking billions in potential revenue.Throughout her career, Michelle has built a strong cross-functional track record spanning R&D, product management, operations, and commercial leadership. She has held key positions at Roche, Merck, BioMarin, and Agilent Technologies, and has also served as an advisor to venture capital firms and startups. Michelle has led new company formations, executed numerous M&A transactions across the U.S., Europe, and Asia, and helped deliver a five-fold increase in the market capitalization of a public company within three years.Michelle earned her Ph.D. in Biochemistry from the University of Washington, conducted postdoctoral research at UC San Francisco, and completed Bioinformatics training at Stanford University.